The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer

Shibata, Kana; Koibuchi, Nobutaka; Sanada, Fumihiro; Katsuragi, Naruto; Kanemoto, Yuko; Tsunetoshi, Yasuo; Ikebe, Shoji; Yamamoto, Koichi; Morishita, Ryuichi; Shimazu, Kenzo; Taniyama, Yoshiaki

doi:https://doi.org/10.3390/cells13171410

The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer

Shibata, Kana; Koibuchi, Nobutaka; Sanada, Fumihiro et al.

Cells, 2024, 13(17), 1410

Number of Access:1,315（2025-08-13 16:06 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/97775

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
Cells_13_17_1410	pdf	None	6.28 MB	129	2024.08.30

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer
Creator	NRID 1000060855104 1000060855104 researchmap permalink kana_shibata kana_shibata CreatorName Shibata, Kana
	NRID 1000030456131 1000030456131 researchmap permalink read0154050 read0154050 CreatorName Koibuchi, Nobutaka
	NRID 1000030722227 1000030722227 researchmap permalink yamato0520 yamato0520 Scopus Author ID 16320033200 16320033200 ORCID 0000-0002-3728-5607 0000-0002-3728-5607 CreatorName Sanada, Fumihiro
	NRID 1000030544506 1000030544506 researchmap permalink katsuragin27 katsuragin27 CreatorName Katsuragi, Naruto
	NRID 1000030924930 1000030924930 CreatorName Kanemoto, Yuko
	CreatorName Tsunetoshi, Yasuo
	CreatorName Ikebe, Shoji
	NRID 1000000528424 1000000528424 ORCID 0000-0003-0107-9315 0000-0003-0107-9315 researchmap permalink kymt0410 kymt0410 Scopus Author ID 55624482466 55624482466 CreatorName Yamamoto, Koichi
	NRID 1000040291439 1000040291439 researchmap permalink read0051652 read0051652 Scopus Author ID 7102241494 7102241494 CreatorName Morishita, Ryuichi
	NRID 1000030448039 1000030448039 researchmap permalink _-23f _-23f Scopus Author ID 7005224756 7005224756 CreatorName Shimazu, Kenzo
	NRID 1000060372611 1000060372611 ORCID 0000-0002-6057-7982 0000-0002-6057-7982 researchmap permalink taniyama taniyama CreatorName Taniyama, Yoshiaki
Subject	periostin
	breast cancer
	stroma
	cancer-associated fibroblasts (CAFs)
	tumor-associated macrophages (TAMs)
	tumor microenvironment (TME)
Description	Shibata Kana, Koibuchi Nobutaka, Sanada Fumihiro, et al. The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer. Cells 13, 1410 (2024); https://doi.org/10.3390/cells13171410.
Abstract	Background: Periostin (POSTN) is a type of matrix protein that functions by binding to other matrix proteins, cell surface receptors, or other molecules, such as cytokines and proteases. POSTN has four major splicing variants (PN1–4), which are primarily expressed in fibroblasts and cancer. We have reported that we should inhibit pathological POSTN (PN1–3), but not physiological POSTN (PN4). In particular, pathological POSTN with exon 17 is present in both stroma and cancer, but it is unclear whether the stroma or cancer pathological POSTN should be suppressed. Methods and Results: We transplanted 4T1 cells (breast cancer) secreting POSTN with exon 17 into 17KO mice lacking POSTN exon 17 to suppress stromal POSTN with exon 17. The results show that 17KO mice had smaller primary tumors and fewer metastases. Furthermore, to suppress cancer POSTN with exon 17, 4T1 cells transfected with POSTN exon 17 skipping oligo or control oligo were transplanted from the tail vein into the lungs. The results show that POSTN exon 17 skipping oligo significantly suppressed lung metastasis. Conclusions: These findings suggest that it is important to suppress POSTN exon 17 in both stroma and cancer. Antibody targeting POSTN exon 17 may be a therapeutic candidate for breast cancer.
Publisher	MDPI AG
Source Title	Cells
Volume (Issue)	13(17)
Page	1410
Date of Issued	2024-08-23
Language	English
Handle URL	https://hdl.handle.net/11094/97775
eISSN	20734409
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.3390/cells13171410
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCTERMS.bibliographicCitation	Cells. 2024, 13(17), p. 1410
DC.title	The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer
DC.creator	Shibata, Kana
	Koibuchi, Nobutaka
	Sanada, Fumihiro
	Katsuragi, Naruto
	Kanemoto, Yuko
	Tsunetoshi, Yasuo
	Ikebe, Shoji
	Yamamoto, Koichi
	Morishita, Ryuichi
	Shimazu, Kenzo
	Taniyama, Yoshiaki
DC.publisher	MDPI AG
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-08-23
DC.identifier	https://doi.org/10.3390/cells13171410
DC.subject	periostin
	breast cancer
	stroma
	cancer-associated fibroblasts (CAFs)
	tumor-associated macrophages (TAMs)
	tumor microenvironment (TME)
DC.description	Shibata Kana, Koibuchi Nobutaka, Sanada Fumihiro, et al. The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer. Cells 13, 1410 (2024); https://doi.org/10.3390/cells13171410.
DCTERMS.abstract	Background: Periostin (POSTN) is a type of matrix protein that functions by binding to other matrix proteins, cell surface receptors, or other molecules, such as cytokines and proteases. POSTN has four major splicing variants (PN1–4), which are primarily expressed in fibroblasts and cancer. We have reported that we should inhibit pathological POSTN (PN1–3), but not physiological POSTN (PN4). In particular, pathological POSTN with exon 17 is present in both stroma and cancer, but it is unclear whether the stroma or cancer pathological POSTN should be suppressed. Methods and Results: We transplanted 4T1 cells (breast cancer) secreting POSTN with exon 17 into 17KO mice lacking POSTN exon 17 to suppress stromal POSTN with exon 17. The results show that 17KO mice had smaller primary tumors and fewer metastases. Furthermore, to suppress cancer POSTN with exon 17, 4T1 cells transfected with POSTN exon 17 skipping oligo or control oligo were transplanted from the tail vein into the lungs. The results show that POSTN exon 17 skipping oligo significantly suppressed lung metastasis. Conclusions: These findings suggest that it is important to suppress POSTN exon 17 in both stroma and cancer. Antibody targeting POSTN exon 17 may be a therapeutic candidate for breast cancer.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	97775
citation_title	The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer
citation_author	Shibata, Kana
	Koibuchi, Nobutaka
	Sanada, Fumihiro
	Katsuragi, Naruto
	Kanemoto, Yuko
	Tsunetoshi, Yasuo
	Ikebe, Shoji
	Yamamoto, Koichi
	Morishita, Ryuichi
	Shimazu, Kenzo
	Taniyama, Yoshiaki
citation_publisher	MDPI AG
citation_language	English
citation_date	2024-08-23
citation_journal_title	Cells
citation_volume	13
citation_issue	17
citation_firstpage	1410
citation_doi	https://doi.org/10.3390/cells13171410
citation_public_url	https://hdl.handle.net/11094/97775

The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer

Link to primary information

Item Information

Show details